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Abstract 
 Genomics is a discipline in genetics that applies recombinant DNA, DNA sequencing 
methods, and bioinformatics to sequence, assemble, and analyze the function and structure of 
genomes, the complete set of DNA within a single cell of an organism. Research into the 
genetics of hypertension has now expanded to genomics. Two approaches have dominated 
this field. One relies on large populations in which the phenotype, hypertension versus no 
hypertension, or hypertension-relevant phenotypes are compared. Genome-wide association 
(GWAS) analyses of (>1 million) common variants identify relevant loci and possible genes 
exerting small effects. Detailed studies on APOL1 and SH2B3 are opening entire new fields 
of research. Family-based Mendelian studies have identified rare variants that exert very large 
effects on blood pressure. Mechanistically, these studies have been a bonanza of new 
information. The approaches are complementary. 
 
Genome-wide association studies 
 Essential (primary) hypertension results from many environmental and genetic factors. 
Candidate-gene, genome-wide linkage, and genome-wide association studies (GWAS) relying 
on single-nucleotide polymorphisms (SNPs) have all given insights into genes relevant for 
essential hypertension. Candidate gene studies have implicated aberrations in aldosterone 
signaling, catecholamine pathways, ion channel regulation, and inflammatory pathways. For 
GWAS, massive sample sizes have been used (>80,000 individuals) to find gene loci that 
exert only modest effects. Memorizing these genes and their variants seems 
counterproductive since thus far they collectively explain only about 2.5% of blood pressure 
variation. Nevertheless, ranking all the currently known findings could theoretically produce a 
genetic risk score indicating a 25% increase in the odds of developing essential hypertension. 
High-throughput massive parallel sequencing and the plummeting costs (currently about 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
- 3 - 
$5000 for an entire human genome) suggest that practitioners will be confronted with this 
kind of information in the future.1 2 
 GWAS have also been performed to study structural and organ-related changes in 
essential hypertension. Examples include the evaluation of arterial stiffness and the 
propensity to develop hypertensive nephrosclerosis.2 Mapping by admixture linkage 
disequilibrium recently led to an important finding in hypertension-related kidney disease in 
African Americans, demonstrating the role of the apolipoprotein L1 (APOL1) and non-muscle 
myosin heavy chain 9 (MYH9) genes. GWAS have also detected associations between kidney 
function and uromodulin (UMOD) and the shroom-related protein (SHROOM3) that may be 
involved in regulating cell shape in certain tissues. 
 Several genes have turned up in numerous GWAS studies on blood pressure, their 
effects are impressive, and their functions should interest hypertension specialists. 
Collaboration between the CHARGE consortium (n = 29,136) and the Global BPgen 
consortium (n = 34,433) produced interesting results. When ten CHARGE SNPs for each trait 
were included in a joint meta-analysis with the Global BPgen Consortium, four CHARGE 
loci attained genome-wide significance (P < 5 × 10-8) for systolic (ATP2B1, CYP17A1, 
PLEKHA7, SH2B3), six for diastolic blood pressure (ATP2B1, CACNB2, CSK-ULK3, 
SH2B3, TBX3-TBX5, ULK4) and one for hypertension (ATP2B1).3 Particularly robust and 
interesting is the SH2B3 gene that encodes SH2B3, also known as LNK, an intracellular 
adaptor protein. LNK regulates cytokine signals that control lympho-hematopoiesis. LNK 
also controls inflammatory CD8 T-cell proliferation. The role of T cells in hypertension, 
particularly blood pressure responses to angiotensin II, is well appreciated.4  But probably the 
most impressive story arising from GWAS studies thus far is the discovery of APOL1 and its 
role in focal sclerosing glomerulosclerosis (FSGS) in African Americans.5  
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 Epigenetics is the study of heritable changes in gene expression or cellular phenotypes 
caused by mechanisms other than changes in the underlying DNA sequence. Several 
molecular processes, including nucleic acid methylation, histone modification, nucleosome 
positioning, transcriptional control with DNA-binding proteins and noncoding RNAs, and 
translation control with microRNAs and RNA-binding proteins orchestrate epigenetic 
changes. Mammalian Sir2 (SIRT1, a NAD+-dependent deacetylase), previously shown to 
extend the lifespan of lower organisms, is a promising target molecule to influence some 
aspects of hypertension, particularly as related to aging.6 An NHLBI working group is 
pursuing the role of epigenetics in essential hypertension.7  
  
Mendelian hypertension 
 Pheochromocytoma can be caused by Mendelian-inherited gene mutations.8 In Europe, 
up to a third of pheochromocytomas represent Mendelian syndromes. Knowledge of these 
syndromes is essential for all hypertension specialists. An activating germ-line mutation in the 
RET proto-oncogene is responsible for an autosomal-dominant syndrome, multiple endocrine 
neoplasia type 2 (MEN 2). RET encodes a transmembrane-receptor tyrosine kinase involved 
in the regulation of cell proliferation and apoptosis. Von Hippel-Lindau (VHL) encodes a 
protein that regulates the activity of hypoxia-inducible factor-alpha. Loss of VHL protein 
function predisposes VHL carriers to both benign and malignant tumors in multiple organs 
including renal cell cancer and pheochromocytoma. Von Recklinghausen’s disease is an 
autosomal-dominant disorder caused by inactivating mutations of the tumor-suppressor gene, 
NF 1 encoding neurofibromin, a GTPase-activating protein involved in the RAS signaling 
cascade and mTOR kinase pathway. Succinate dehydrogenase enzyme complex consists of 
four subunits encoded by SDHA, SDHB, SDHC, and SDHD. For correct function of the 
SDHA subunit, a cofactor of flavin-adenine dinucleotide is necessary, SDHAF2. All five 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
- 5 - 
genes are associated with pheochromocytoma. Finally, the tumor-suppressor gene, TMEM-
127 encoding a transmembrane protein, has recently been identified as a new 
pheochromocytoma gene.  
 Somatic KCNJ5 mutations explain a subset of aldosterone-producing adenomas, the 
most frequent secondary cause of arterial hypertension.9,10 KCNJ5 encodes the inwardly 
rectifying K+ channel Kir3.4 that exists both as homotetramers and heterotetramers with 
Kir3.1. Mutations result in loss of channel selectivity, with increased sodium conductance 
leading to membrane depolarization. In zona glomerulosa cells that produce aldosterone, 
membrane depolarization leads to opening of voltage-activated Ca2+ channels with activation 
of the calcium-signaling pathway. A similar heterozygous-inherited germinal KCNJ5 
mutation, T158A, located in the same conserved region, was described in a kindred with 
Mendelian hyperaldosteronism. The regulation of aldosterone secretion is exerted to a 
significant degree by activation of membrane potassium and calcium channels or pumps. 
Thus, it is not surprising that the known causes of disorders of aldosterone secretion in APA 
have been channelopathies, which activate mechanisms that increase aldosterone synthesis.11 
 Students of hypertension should be keenly aware of Mendelian syndromes causing 
hypertension (Figure) that are associated with low plasma renin activity (PRA). Familial 
hyperaldosteronism type I (FH-I), also known as glucocorticoid-remediable aldosteronism 
(GRA), was the first form of Mendelian hypertension to be recognized as a single-gene 
hypertensive disorder.12 The genetic defect features a hybrid or chimeric gene on chromosome 
8q consisting of the regulatory region of the 11β-hydroxylase gene, CYP11B1, coupled with 
the structural region of the aldosterone synthase gene, CYP11B2. The mode of inheritance is 
autosomal dominant with complete penetrance. The chimeric gene results in increased 
aldosterone production, as well as aberrant metabolites. 
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 Familial hyperaldosteronism type II (FH-II) is clinically indistinguishable from 
sporadic forms of primary hyperaldosteronism due to bilateral adrenal hyperplasia. The 
genetic abnormality has been mapped to chromosome 7p22. In familial hyperaldosteronism 
type I (FH-I), glucocorticoids ameliorate aldosterone overproduction, since ACTH drives the 
chimeric gene. In contrast, hypertension in FH-II is unresponsive to glucocorticoids; however, 
spironolactone is effective. Congenital adrenal hyperplasia is inherited in an autosomal 
recessive manner. When 21-hydroxylase (CYP21A2) is deficient patients waste salt and are 
normotensive. However, in 11β-hydroxylase (CYP11B1) and 17α-hydroxylase (CYP17) 
deficiencies, production of deoxycorticosterone (DOC) is increased, leading to hypertension. 
Investigators described a mutation in the gene encoding the mineralocorticoid receptor 
(MCR), a leucine-for-serine substitution at codon 810, which lies in the hormone-binding 
domain of the MCR. The mutation causes the receptor to be constitutively active and changes 
the MRC specificity such that the steroid hormones lacking a 21-hydroxyl group that are 
normally antagonistic (progesterone and cortisone), act as agonists. In the kidney, 11β-
hydroxysteroid dehydrogenase-2 (11β-HSD-2) converts cortisol to cortisone, which does not 
activate the renal MCR. This mechanism protects the collecting tubules from inappropriate 
activation of the MCR by circulating cortisol. The autosomal recessive syndrome of apparent 
mineralocorticoid excess (AME) causes severe hypertension through mutations in the 11β-
HSD-2 gene, which render the enzyme ineffective. This state-of-affairs allows cortisol, which 
circulates at much higher concentrations than aldosterone, to saturate the MCR and induce 
hypertension and hypokalemia. 
Liddle’s syndrome is an autosomal dominant disorder causing hyperactivity of the 
amiloride-sensitive sodium channel (ENaC) in the cortical collecting tubule.13 Genetic studies 
showed that mutations of the beta or gamma subunits of ENaC (chromosome 16p) cause 
deletions of proline-rich regions. These regions regulate ENaC activity because they facilitate 
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binding of Nedd4, a regulatory repressor that promotes channel degradation. The inability of 
beta and gamma subunits to bind Nedd4 results in constitutive expression of sodium channels 
at the apical surface of principal cells, leading to increased rates of sodium reabsorption, 
volume expansion, and hypertension. 
Mutations of the serine-threonine (with no lysine) kinases, WNK1 and WNK4, cause 
pseudohypoaldosteronism type II (also called Gordon’s syndrome). Wild-type WNK1 and 
WNK4 inhibit the thiazide- sensitive Na–Cl co-transporter in the distal tubule.14 Mutations of 
these proteins are associated with gain of function and increased co-transporter activity, 
excessive chloride and sodium reabsorption, and volume expansion. Hyperkalemia, another 
hallmark of this syndrome, might be a function of diminished sodium delivery to the cortical 
collecting tubule. Sodium reabsorption provides the driving force for potassium excretion, 
which is mediated by the renal outer medullary potassium channel ROMK). Alternatively, the 
same mutations in WNK4 that increase Na-Cl co-transporter activity could inhibit ROMK. 
Interestingly, other genetic causes of pseudohypoaldosteronism type II exist. 
Investigators recently conducted exome sequencing to identify mutations in kelch-like 3 
(KLHL3) or cullin 3 (CUL3) in pseudohypoaldosteronism type II patients from 41 unrelated 
families. KLHL3 mutations were either recessive or dominant, whereas CUL3 mutations are 
dominant and predominantly de novo.15 Disease features in these families were reversed by 
thiazide diuretics, which inhibit the Na-Cl cotransporter in the distal nephron of the kidney. 
KLHL3 and CUL3 are expressed in this location, suggesting a mechanistic link between 
KLHL3 and CUL3 mutations, increased Na-Cl reabsorption, and disease pathogenesis. The 
findings demonstrate the utility of exome sequencing in disease gene identification despite the 
combined complexities of locus heterogeneity, mixed models of transmission and frequent de 
novo mutation, and establish a fundamental role for KLHL3 and CUL3 in blood pressure, 
potassium, and pH homeostasis. 
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Recently a form of Mendelian metabolic syndrome was described. Investigators 
identified three large families with coinheritance of early-onset coronary artery disease, 
central obesity, hypertension, and diabetes.16 A founder mutation was identified in DYRK1B, 
substituting cysteine for arginine at position 102 in the highly conserved kinase-like domain. 
A hyperactivated DYRK1B promoted the expression of the key gluconeogenic enzyme 
glucose-6-phosphatase. These exciting findings indicate a role for DYRK1B in adipogenesis 
and glucose homeostasis and associate its altered function with an inherited form of the 
metabolic syndrome. 
Autosomal-dominant hypertension with brachydactyly is particularly interesting since 
the phenotype does not exhibit salt sensitivity and since the renin-angiotensin-aldosterone 
system exhibits normal values.17 Since a complex genetic rearrangement was associated with 
this syndrome that included deletions, reinsertions, and inversions, we had postulated an 
epigenetic explanation for this syndrome.18 The advent of genome-wide sequencing at 
affordable prices, has led us to the discovery of mutations in a gene within the linkage interval 
that is likely responsible for both phenotypes. We have found not precisely identical but 
closely related mutations in five other families with this syndrome (unpublished 
observations). The mutation leads to a direct increase in peripheral vascular resistance 
throughout the entire vascular tree. 
The Mendelian forms of hypertension are generally not difficult to diagnose. A careful 
family history is of course helpful. All, except for autosomal-dominant hypertension with 
brachydactyly, feature low PRA. In GRA, aldosterone levels are quite elevated but decrease 
with replacement prednisone. In patients with MCR mutations and AME, PRA and 
aldosterone levels are both low. Licorice gluttony should be in the differential diagnosis. In 
Liddle’s syndrome, aldosterone levels are also low. Thus, spironolactone is helpful while 
blocking ENaC is effective. In persons with WNK1 and WNK4 mutations aldosterone values 
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are normal to elevated. Furthermore, the mild metabolic acidosis and hyperkalemia should be 
a useful clue, as opposed to mild metabolic alkalosis and hypokalemia, as featured by other 
Mendelian conditions. Autosomal-dominant hypertension with brachydactyly can be 
diagnosed with a handshake. The brachydactyly is a type E brachydactyly, which is not 
uncommon. Since essential hypertension is also common, we have worked up several families 
with autosomal-dominant type E brachydactyly that did not have the syndrome described 
above. But the effort has led us to discover other genetic findings, including a long noncoding 
RNA that leads to brachydactyly.19 
 One difficult question to answer is: why have the GWAS studies not identified the 
gene loci of Mendelian syndromes, since the genes responsible for these conditions are clearly 
highly related to hypertension? The effects of alleles in many genes contribute to common 
complex diseases such as hypertension. Whether risk alleles comprise a small number of 
common variants or many rare independent mutations at trait loci is largely unknown. 
However, this possibility has been carefully explored. Investigators have screened members 
of the Framingham Heart Study (FHS) for variation in three genes, namely SLC12A3 
(NCCT), SLC12A1 (NKCC2), and KCNJ1 (ROMK) that cause rare recessive diseases 
featuring large reductions in blood pressure.20 Comparative genomics, genetics and 
biochemistry were used to identify subjects with mutations proven or inferred to be 
functional. These mutations were all heterozygous and rare. They produced clinically 
significant blood pressure reduction and likely protected from the development of 
hypertension. The findings implicated many rare alleles that alter renal salt handling in blood 
pressure variation in the general population, and identified alleles with health benefit that 
were nonetheless under purifying selection. The observations have implications for the 
genetic architecture of hypertension. Furthermore, the presence of these variants in the general 
population could confound GWAS searches for hypertension genes. 
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Perspective 
 Genomics has come to hypertension-related research. In the last 15 years, the costs of 
total-genome sequencing have decreased from 200 million dollars to 5000 dollars, within the 
range of clinical investigators. Furthermore, ancillary technology and availability of powerful 
bioinformatics has made hypertension-related research not only tremendously exciting but 
also within the grasp of clinical investigators and interested clinicians. Important is the 
continuous participation of clinicians in this process. There is little reason to be intimidated 
by the technical aspects; help is readily at hand. Important is the issue that hypertension 
specialists stay tuned to the latest development. This research will steadily reduce the 
numbers of patients with “essential” hypertension and continually increase the patients with 
“secondary” hypertension. These advances will make “personalized” medicine possible. 
 
 
Figure legend. 
 Figure. Mendelian hypertension thus far influences salt transport across the nephron 
(tubule to blood vessel. Shown are the nephron areas (hatched) in the distal tubule and 
collection duct (all fine-tuning sites). GRA, AME, and MCR are represented across the entire 
area. Na-Cl co-transporter is mostly in the distal tubule. ENaC also expends a great area. 
ROMK, as influenced by WNK, is also universally expressed in the distal nephron. 
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